Medigene Value Stock - Dividend - Research Selection
Market price: 4,95 EUR
Medigene Fundamental data and company key figures of the share
|Annual reports in EUR|
|Net operating cash flow||-16.423.000|
|Free cash flow||-17.851.000|
|Liabilities & Shareholders equity||109.215.000|
|Diluted shares outstanding||24.644.400|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||147.956.064,00 USD|
|Indices||CDAX,Prime All Share|
|Raw Data Source||IFRS in Millionen EUR|
|Stock Split||2013-09-03,1.0000/4.0000; 2004-10-27,2105.000000/2104.000000; 2004-03-08,1214.000000/1211.000000|
Description of the company
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; EndoTAG-1 for the treatment of solid tumors; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and a research collaboration with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Martinsried, Germany.